Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Chuikyo Backs MHLW Proposal on Fertility Treatment Coverage
December 16, 2021
- Japan Panel OKs Moderna COVID-19 Vaccine for Booster Use
December 16, 2021
- Japan to Boost Pharma Startup Ecosystem via VC Certification Program, Allocates 50 Billion Yen in FY2021 Extra Budget
December 15, 2021
- Aducanumab Up for Japan Advisory Panel Review on December 22
December 15, 2021
- MHLW Calls for Lifting of Shipment Restrictions for 130 Generic API/Specifications after Survey Finds YOY Rise in Supplies
December 14, 2021
- Doctor, Pharmacist Reps Call for Expanding Fees for Biosimilars: Chuikyo
December 13, 2021
- LDP Project Team to Compile Proposal to Move Up Booster Interval
December 13, 2021
- METI to Dole Out Support for “Dual-Use” Production Bases to Boost Pandemic Preparedness
December 13, 2021
- Sakigake Status Withdrawn for Takeda’s Pevonedistat: MHLW
December 10, 2021
- Fiscal Discipline for Drug Spending Could Be Discussed towards FY2023: MOF Budget Examiner
December 10, 2021
- E Keppra Generics from 12 Firms to Join NHI Price List, Patanol and Velcade AGs Too
December 9, 2021
- Payers Want Low-Generic Fee Cuts Applied to Medical Institutions Too: Chuikyo
December 9, 2021
- No Chuikyo Members Call for Formulary Incentives under Medical Fee Schedule
December 9, 2021
- Moderna COVID-19 Booster Up for Panel Review on Dec. 15
December 9, 2021
- MHLW Warns against Hoarding on 17 APIs as Hitachi Fire Stirs Supply Worries
December 8, 2021
- Shorter Booster Interval for All Citizens Difficult: Health Minister
December 8, 2021
- Written Pledge Rule on Generic Listing to Continue after 2021; Companies Feel Pressure for Stable Supplies
December 7, 2021
- BMS’ Second CAR-T Therapy Ide-Cel in Line for Approval in January
December 7, 2021
- MHLW to Prepare List of Priority Infectious Diseases by March-End, Set Up Study Group in December
December 7, 2021
- Japan Panels Agree to Add Myocarditis as ADRs for Pfizer, Moderna Vaccines
December 6, 2021
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…